MODERN ASPECTS OF NEOADJUVANT POLYCHEMOTHERAPY IN TREATMENT OF PATIENTS WITH BREAST CANCER
Neoadjuvant polychemotherapy (NPCT) can op- timize surgical treatment of patients with breast cancer, favor- ing in the operations with the mainteinance of breast gland. The substantial increase of frequency of organopreserved op- erations is provided by using NPCT of taxans: in combina- tion with anthracyclines or consistently with anthracycline containing medical regimens. For postmenopause patients with hormone sensitive breast cancer the possibility of oper- ations with the maintaining of breast gland can provide neo- adjuvant endocrinotherapy. An important prognostic sign is frequency of complete patomorphological regression (pCR) after NPCT, and also the state of regional lymphonods. Af- ter NPCT pCR is observed more frequently at hormone in- dependent breast cancer. Duration of NPCT was not deter- mined (but not less than 4 cycles); a neoadjuvant hormono- therapy must be conducted at least 3–4 months.